Presentation is loading. Please wait.

Presentation is loading. Please wait.

Secondary Resistance to Erlotinib: Acquired T790M Mutation and Small-Cell Lung Cancer Transformation in the Same Patient  Vincent Fallet, MD, Anne-Marie.

Published byBenjamin Magnussen Modified over 5 years ago

Similar presentations

Presentation on theme: "Secondary Resistance to Erlotinib: Acquired T790M Mutation and Small-Cell Lung Cancer Transformation in the Same Patient  Vincent Fallet, MD, Anne-Marie."— Presentation transcript:

1 Secondary Resistance to Erlotinib: Acquired T790M Mutation and Small-Cell Lung Cancer Transformation in the Same Patient  Vincent Fallet, MD, Anne-Marie Ruppert, MD, Virginie Poulot, Roger Lacave, MD, PhD, Laure Belmont, MD, Martine Antoine, MD, Jacques Cadranel, MD, PhD, Marie Wislez, MD, PhD, Armelle Lavolé, MD  Journal of Thoracic Oncology  Volume 7, Issue 6, Pages (June 2012) DOI: /JTO.0b013e31824fea45 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 CT scan evolution. A, June 2010: Alveolar opacity of the right upper lobe before erlotinib introduction. B, Major response after 2 months with erlotinib. C, June 2011: Mass of the right upper lobe corresponding to the SCLC transformation. D, Response of the right upper lobe mass with progression of the alveolar opacity, after one cycle of cisplatin and etoposide with erlotinib continuation. CT, computed tomography; SCLC, small-cell lung cancer. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31824fea45) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Resistance as small-cell lung cancer. A, Pathological analysis of bronchial biopsy specimen showing SCLC transformation. Small cells with round or oval nuclei and sparse cytoplasm. B, Sequencing chromatogram showing an exon 19 EGFR deletion (black bar) in DNA extract from SCLC biopsy specimen. SCLC, small cell lung cancer; EGFR, endothelial growth factor receptor. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31824fea45) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Resistance as T790M mutation. A, Cytological analysis of bronchial aspirate showing adenocarcinoma cells. Monolayered sheet of cells with uniform, round nuclei; fine nuclear chromatin; and intranuclear cytoplasmic inclusion bodies. B, Sequencing chromatograms of exon 20 for EGFR demonstrate the T790M mutation (c.2369C > T; p.Thr790Met) at exon 20) in DNA extract from adenocarcinoma cells from bronchial aspirate specimen. A red arrow indicates the mutation at nucleotide 2369 (C > K [C + T]), which leads to substitution of Threonine (ACG) for Methionine (ATG) at position 790. EGFR, endothelial growth factor receptor. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e31824fea45) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Secondary Resistance to Erlotinib: Acquired T790M Mutation and Small-Cell Lung Cancer Transformation in the Same Patient  Vincent Fallet, MD, Anne-Marie."

Similar presentations

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,
Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung.
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of.

Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of.
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells  Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,
MET Mutation Associated with Responsiveness to Crizotinib

MET Mutation Associated with Responsiveness to Crizotinib
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F
Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report  Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report  Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.
Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion  Eckart Laack, MD, Ronald.

Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion  Eckart Laack, MD, Ronald.

Similar presentations

Ads by Google